Wallack M K, McNally K, Michaelides M, Bash J, Bartolucci A, Siegler H, Balch C, Wanebo H
Am Surg. 1986 Mar;52(3):148-51.
Forty-eight patients with nonrecurrent high risk Stage I and II malignant melanoma were treated with Vaccinia Melanoma Oncolysates (VMO). Six different dose levels and two different treatment regimens were tested. Thirty-two out of 48 patients completed the 12 months of therapy. Side effects were mild to moderate. Twenty-eight out of 48 patients remain free from disease with a mean survival of 19 months, while 20/48 patients have recurred with a mean time to recurrence of 6 months.
48例非复发性高危I期和II期恶性黑色素瘤患者接受了牛痘黑色素瘤溶瘤产物（VMO）治疗。测试了六种不同剂量水平和两种不同治疗方案。48例患者中有32例完成了12个月的治疗。副作用为轻至中度。48例患者中有28例无疾病复发，平均生存期为19个月，而48例患者中有20例复发，平均复发时间为6个月。
